

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN OBINUTUZUMAB
PRONUNCIATION oh" bi nue tooz' ue mab
THERAPEUTIC CLAIM Treatment of lymphoma, oncology

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 κ -chain, dimer
2. Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (membrane-spanning 4-domains subfamily A member 1, B-lymphocyte surface antigen B1, Leu-16 or Bp35)), humanized mouse monoclonal GA101 des-CH3¹⁰⁷-K- γ 1 heavy chain (222-219')-disulfide with humanized mouse monoclonal GA101 κ light chain dimer (228-228":231-231")-bisdisulfide

MOLECULAR FORMULA $C_{6512}H_{10060}N_{1712}O_{2020}S_{44}$
MOLECULAR WEIGHT 146.1 kDa
TRADEMARK None as yet
SPONSOR Genentech, Roche
CODE DESIGNATION RO 5072759, huMAB<CD20>, GA101
CAS REGISTRY NUMBER 949142-50-1

NOTE: This statement supersedes adopted name *afutuzumab* (N08/42), and statement N09/109. The adoption of *afutuzumab* is hereby rescinded.